Darwin Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Darwin Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$65	Buy	+2	New	+$69	﹤0.01%	1152

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Darwin Wealth Management's VKTX Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Viking Therapeutics (VKTX) in Q3 2026: 2 shares worth $65. The stake represents ﹤0.01% of the portfolio and ranks #1152 among its holdings.

227 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

Darwin Wealth Management held 2 shares of Viking Therapeutics worth $65 as of Q3 2026.
Viking Therapeutics was a new Darwin Wealth Management position in Q3 2026.
Viking Therapeutics made up ﹤0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #1152 holding.
227 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.